Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EOLS Stock Forecast 2025-2026
$6.85
Current Price
$444.02M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to EOLS Price Targets
+192.0%
To High Target of $20.00
+184.7%
To Median Target of $19.50
+104.4%
To Low Target of $14.00
EOLS Price Momentum
-4.3%
1 Week Change
+4.4%
1 Month Change
-45.9%
1 Year Change
-38.0%
Year-to-Date Change
-60.0%
From 52W High of $17.12
+20.0%
From 52W Low of $5.71
📊 TOP ANALYST CALLS
Did EOLS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Evolus is one of their latest high-conviction picks.
Latest EOLS Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, EOLS has a bullish consensus with a median price target of $19.50 (ranging from $14.00 to $20.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $6.85, the median forecast implies a 184.7% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 192.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EOLS Analyst Ratings
6
Buy
1
Hold
0
Sell
EOLS Price Target Range
Low
$14.00
Average
$19.50
High
$20.00
Current: $6.85
Latest EOLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EOLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $19.00 |
| Sep 8, 2025 | BTIG | Sam Eiber | Buy | Reiterates | $18.00 |
| Aug 6, 2025 | Needham | Serge Belanger | Hold | Downgrade | $22.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $20.00 |
| Aug 6, 2025 | BTIG | Sam Eiber | Buy | Maintains | $18.00 |
| May 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $22.00 |
| Apr 17, 2025 | BTIG | Sam Eiber | Buy | Initiates | $21.00 |
| Apr 10, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Apr 9, 2025 | Needham | Serge Belanger | Buy | Reiterates | $22.00 |
| Mar 5, 2025 | Needham | Serge Belanger | Buy | Reiterates | $22.00 |
| Mar 5, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $25.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Jan 27, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $22.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Jan 21, 2025 | Needham | Serge Belanger | Buy | Reiterates | $22.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $27.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
Evolus Inc. (EOLS) Competitors
The following stocks are similar to Evolus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evolus Inc. (EOLS) Financial Data
Evolus Inc. has a market capitalization of $444.02M with a P/E ratio of -8.5x. The company generates $285.82M in trailing twelve-month revenue with a -20.5% profit margin.
Revenue growth is +12.9% quarter-over-quarter, while maintaining an operating margin of -14.7% and return on equity of -913.1%.
Valuation Metrics
Market Cap
$444.02M
Enterprise Value
$555.38M
P/E Ratio
-8.5x
PEG Ratio
0.4x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+12.9%
Gross Margin
+66.5%
Operating Margin
-14.7%
Net Margin
-20.5%
EPS Growth
+12.9%
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
2.0x
Debt/Equity
-5.4x
ROE
-913.1%
ROA
-10.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Evolus Inc. (EOLS) Business Model
About Evolus Inc.
What They Do
Provides aesthetic dermatology solutions for non-surgical procedures.
Business Model
Evolus Inc. generates revenue primarily through the sales of its flagship product, Jeuveau, which is a botulinum toxin formulation designed for cosmetic use. The company targets healthcare and beauty professionals who seek to offer innovative, cost-effective aesthetic treatments to their clients, thereby expanding their service offerings and meeting the growing demand for non-invasive cosmetic procedures.
Additional Information
Headquartered in Newport Beach, California, Evolus Inc. operates within the highly competitive aesthetic medicine sector and is publicly traded. Its focus on innovation and strategic positioning allows it to play a significant role in the market for cosmetic enhancements, attracting the attention of investors and industry stakeholders.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
329
CEO
Mr. David Moatazedi
Country
United States
IPO Year
2018
Website
www.evolus.comEvolus Inc. (EOLS) Latest News & Analysis
Latest News
Quick Summary
Evolus, Inc. granted 17,871 stock options and 45,063 RSUs to 13 newly hired non-executive employees, approved by the compensation committee.
Why It Matters
Evolus's grant of stock options and RSUs to new employees may signal growth potential and commitment to talent retention, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Evolus, Inc. (EOLS) will host its Q3 2025 earnings call on November 5, 2025, at 4:30 PM EST, featuring key executives and analysts from various firms.
Why It Matters
Evolus' Q3 earnings call provides critical insights into its financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Evolus, Inc. (NASDAQ: EOLS) reported double-digit growth for Q3 2025, demonstrating strong performance and disciplined expense management amid a challenging market.
Why It Matters
Evolus reported double-digit growth in Q3 2025, indicating strong performance amid market challenges. This suggests resilience and potential for future profitability, positively impacting investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Evolus, Inc. (EOLS) reported a quarterly loss of $0.14 per share, better than the expected loss of $0.19, and an improvement from a $0.19 loss per share a year ago.
Why It Matters
Evolus's smaller-than-expected quarterly loss indicates potential operational improvement, which may boost investor confidence and influence stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Evolus (EOLS) may not achieve an earnings beat in its upcoming report due to lacking the necessary key ingredients. Investors should note the key expectations ahead.
Why It Matters
Evolus may underperform in its earnings report, signaling potential weakness in financial performance, which could negatively impact stock prices and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Evolus, Inc. (NASDAQ: EOLS) will participate in the Stifel Healthcare Conference with a fireside chat on November 11, 2025, at 11:20 AM ET. Access details are on their Investor Relations page.
Why It Matters
Evolus's management participation at the Stifel Healthcare Conference signals engagement with investors, potentially boosting investor confidence and interest in the company’s growth and strategy.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About EOLS Stock
What is Evolus Inc.'s (EOLS) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Evolus Inc. (EOLS) has a median price target of $19.50. The highest price target is $20.00 and the lowest is $14.00.
Is EOLS stock a good investment in 2026?
According to current analyst ratings, EOLS has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EOLS stock?
Wall Street analysts predict EOLS stock could reach $19.50 in the next 12 months. This represents a 184.7% increase from the current price of $6.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evolus Inc.'s business model?
Evolus Inc. generates revenue primarily through the sales of its flagship product, Jeuveau, which is a botulinum toxin formulation designed for cosmetic use. The company targets healthcare and beauty professionals who seek to offer innovative, cost-effective aesthetic treatments to their clients, thereby expanding their service offerings and meeting the growing demand for non-invasive cosmetic procedures.
What is the highest forecasted price for EOLS Evolus Inc.?
The highest price target for EOLS is $20.00 from Douglas Tsao at HC Wainwright & Co., which represents a 192.0% increase from the current price of $6.85.
What is the lowest forecasted price for EOLS Evolus Inc.?
The lowest price target for EOLS is $14.00 from at , which represents a 104.4% increase from the current price of $6.85.
What is the overall EOLS consensus from analysts for Evolus Inc.?
The overall analyst consensus for EOLS is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.50.
How accurate are EOLS stock price projections?
Stock price projections, including those for Evolus Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:51 PM UTC